当前位置： SCI文献检索 > ENDOCRINE-RELATED CANCER期刊下所有文献 > Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

Abstract：

:Neuroendocrine tumours (NET) of the gastroenteropancreatic system comprise a malignant entity with a low incidence. Only limited information is available on long-term clinical outcome and clinically applicable prognostic factors. We performed a retrospective analysis of a large, well-characterized centre-based patient cohort of 399 patients with histologically proven NET. Data were analysed according to epidemiological, clinical and histopathological characteristics. Detailed survival analyses using the Kaplan-Meier method were performed. Prognostic factors were tested by log-rank testing and independent risk factors were analysed using a Cox regression model. In the studied cohort, primary tumours originated in the fore-, mid- and hindgut in 46.1, 37.1 and 4.5% respectively. Extra-intestinal or unknown primary tumours were present in 8.4 and 10.5% respectively. Distant metastasis was present at initial diagnosis in 69.4%. Most frequent metastatic sites were liver (85%), peritoneal cavity (18%), bones (8%), other intra-abdominal sites (6%) and lungs (4%). Overall, 5- and 10-year survival rates were 78 and 63% respectively. Time to progression after initial diagnosis was significantly shorter in pancreatic as compared with ileal NET. Survival analysis revealed significantly better clinical outcome for primary tumours smaller than 25 mm, absence of metastasis, absence of any clinical symptoms, positive immunohistochemical staining for chromogranin A and a lower Ki67 index. These results were confirmed as independent by multivariate analysis. Therefore, this large retrospective analysis of a well-documented cohort of patients with NET demonstrates several prognostic factors of clinical relevance and wide availability, which should be considered for risk stratification in the management of NET.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Pape UF,Berndt U,Müller-Nordhorn J,Böhmig M,Roll S,Koch M,Willich SN,Wiedenmann B

doi

10.1677/ERC-08-0017

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

1083-97

issue

4

eissn

1351-0088

issn

1479-6821

pii

ERC-08-0017

journal_volume

15

pub_type

杂志文章

相关文献

ENDOCRINE-RELATED CANCER文献大全
  • Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer.

    abstract：:Colony-stimulating factor 1 (CSF1) is a key regulator of mammary gland development, and a modulator of tissue macrophages. Expression of the CSF1 receptor gene C-FMS (CSF1R) is strongly associated with poor outcome in breast cancer and results in tumor cell invasiveness and pro-metastatic behavior in vitro. However, C...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-13-0198

    authors： Aharinejad S,Salama M,Paulus P,Zins K,Berger A,Singer CF

    更新日期：2013-10-14 00:00:00

  • Risks of breast, endometrial, and ovarian cancers after twin births.

    abstract：:The concentrations of endogenous hormones differ between women with twin and singleton births, with a possible influence on the risk of cancer. We used the nationwide Swedish Family-Cancer Database, including 30,409 women with a twin birth, to examine the subsequent risks of breast, endometrial, and ovarian cancers. R...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/ERC-07-0088

    authors： Ji J,Försti A,Sundquist J,Hemminki K

    更新日期：2007-09-01 00:00:00

  • Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

    abstract：:Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-Pa...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-18-0100

    authors： Krauss T,Ferrara AM,Links TP,Wellner U,Bancos I,Kvachenyuk A,Villar Gómez de Las Heras K,Yukina MY,Petrov R,Bullivant G,von Duecker L,Jadhav S,Ploeckinger U,Welin S,Schalin-Jäntti C,Gimm O,Pfeifer M,Ngeow J,Hasse-Laza

    更新日期：2018-09-01 00:00:00

  • 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas.

    abstract：:The combination of pituitary adenomas (PA) and phaeochromocytomas (phaeo) or paragangliomas (PGL) is a rare event. Although these endocrine tumours may occur together by coincidence, there is mounting evidence that, in at least some cases, classical phaeo/PGL-predisposing genes may also play a role in pituitary tumori...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-15-0241

    authors： O'Toole SM,Dénes J,Robledo M,Stratakis CA,Korbonits M

    更新日期：2015-08-01 00:00:00

  • Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia.

    abstract：:Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized in man by parathyroid, pancreatic, pituitary and adrenal tumours. The MEN1 gene encodes a 610-amino acid protein (menin) which is a tumour suppressor. To investigate the in vivo role of menin, we developed a mouse model, by dele...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/ERC-09-0082

    authors： Harding B,Lemos MC,Reed AA,Walls GV,Jeyabalan J,Bowl MR,Tateossian H,Sullivan N,Hough T,Fraser WD,Ansorge O,Cheeseman MT,Thakker RV

    更新日期：2009-12-01 00:00:00

  • PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A.

    abstract：:Genetic variants in components of the protein kinase A (PKA) enzyme have been associated with various defects and neoplasms in the context of Carney complex (CNC) and in isolated cases, such as in primary pigmented nodular adrenocortical disease (PPNAD), cortisol-producing adrenal adenomas (CPAs), and various cancers....

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-20-0309

    authors： Espiard S,Drougat L,Settas N,Haydar S,Bathon K,London E,Levy I,Faucz FR,Calebiro D,Bertherat J,Li D,Levine MA,Stratakis CA

    更新日期：2020-11-01 00:00:00

  • The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.

    abstract：:Cancers of the reproductive tract account for 12% of all malignancies in women. As previous studies have shown that oestrogen metabolites can cause apoptosis, we characterised the effect of oestrogen and oestrogen metabolites on non-cancerous and cancerous human endometrial cells. Herein, we demonstrate that 2-methoxy...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/ERC-07-0008

    authors： Kato S,Sadarangani A,Lange S,Villalón M,Brañes J,Brosens JJ,Owen GI,Cuello M

    更新日期：2007-06-01 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs.

    abstract：:The 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) held in Houston, TX, USA, focused on emerging topics in the pathogenesis and therapy of malignant endocrine tumors associated with MEN syndromes. With MEN-2 syndromes, the most common malignancy is medullary thyroid carcinoma (MTC). In the spirit o...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-20-0110

    authors： Dadu R,Bagheri-Yarmand R,Ringel MD,Grubbs EG,Zafereo M,Cote G,Gagel RF,Robinson BG,Shaw KR,Hu MI

    更新日期：2020-08-01 00:00:00

  • Aromatase inhibitors and their antitumor effects in model systems.

    abstract：:The potential of aromatase (estrogen synthetase) within the breast to provide a significant source of estrogen mediating tumor proliferation is suggested by studies reporting 4- to 6-fold higher estrogen levels in tumors than in plasma of postmenopausal patients with breast cancer. Recent studies in our laboratory hav...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/erc.0.0060205

    authors： Brodie A,Lu Q,Liu Y,Long B

    更新日期：1999-06-01 00:00:00

  • Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.

    abstract：:The clinical course of medullary thyroid carcinoma (MTC) associated with the MEN2A syndrome as well as of sporadic MTC shows considerable heterogeneity. The disease picture varies not only between the same RET proto-oncogene mutation carriers but also among sporadic MTC patients with no RET germinal mutations, which s...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-17-0452

    authors： Kaczmarek-Ryś M,Ziemnicka K,Pławski A,Budny B,Michalak M,Hryhorowicz S,Hoppe-Gołębiewska J,Boruń P,Gołąb M,Czetwertyńska M,Sromek M,Szalata M,Ruchała M,Słomski R

    更新日期：2018-04-01 00:00:00

  • 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

    abstract：:177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncomm...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-18-0509

    authors： Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

    更新日期：2019-04-01 00:00:00

  • MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

    abstract：:The high degree of conservation in microRNA from Caenorhabditiselegans to humans has enabled relatively rapid implementation of findings in model systems to the clinic. The convergence of the capacity for genomic screening being implemented in the prevailing precision medicine initiative and the capabilities of microR...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-16-0525

    authors： Smith B,Agarwal P,Bhowmick NA

    更新日期：2017-05-01 00:00:00

  • Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.

    abstract：:There are currently few successful therapies for castration-resistant prostate cancer (CRPC). CRPC is thought to result from augmented activation of the androgen/androgen receptor (AR) signaling pathway, which could be enhanced by AR cofactors. In this study, heterochromatin protein 1beta (HP1beta), but not HP1alpha o...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/ERC-09-0321

    authors： Shiota M,Song Y,Yokomizo A,Tada Y,Kuroiwa K,Eto M,Oda Y,Inokuchi J,Uchiumi T,Fujimoto N,Seki N,Naito S

    更新日期：2010-05-18 00:00:00

  • HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Early thyroidectomy in multiple endocrine neoplasia: a four decade experience.

    abstract：:Forty years ago, physicians caring for the J-kindred, a 100+ member family with multiple endocrine neoplasia type 2A (MEN2A), hypothesized that early thyroidectomy based on measurement of the biomarker calcitonin could cure patients at risk for development of medullary thyroid carcinoma (MTC). We re-evaluated 22 famil...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-20-0108

    authors： Grubbs EG,Lechan RM,Edeiken-Monroe B,Cote GJ,Trotter C,Tischler AS,Gagel RF

    更新日期：2020-08-01 00:00:00

  • Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.

    abstract：:Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioi...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-15-0555

    authors： Viola D,Valerio L,Molinaro E,Agate L,Bottici V,Biagini A,Lorusso L,Cappagli V,Pieruzzi L,Giani C,Sabini E,Passannati P,Puleo L,Matrone A,Pontillo-Contillo B,Battaglia V,Mazzeo S,Vitti P,Elisei R

    更新日期：2016-04-01 00:00:00

  • A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation.

    abstract：:Postmenopausal women on estrogen replacement therapy (ERT) have a reduced risk of developing colon cancer compared with postmenopausal women not on ERT, suggesting a role for estradiol (E2) in protection against this disease. To determine whether E2 protects against inflammation-associated colon cancer when administer...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-12-0308

    authors： Armstrong CM,Billimek AR,Allred KF,Sturino JM,Weeks BR,Allred CD

    更新日期：2013-06-27 00:00:00

  • Mouse models of transforming growth factor beta impact in breast development and cancer.

    abstract：:It is now recognized that transforming growth factor beta (TGF-beta) is an important factor that regulates normal breast development as well as breast cancer. Genetically engineered mouse models have been used to determine the role and mechanism of TGF-beta action in normal development and diseases of the breast. Usin...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1677/erc.1.00936

    authors： Serra R,Crowley MR

    更新日期：2005-12-01 00:00:00

  • Multiple endocrine neoplasia type 1.

    abstract：:Combined clinical and laboratory investigations of multiple endocrine neoplasia type 1 (MEN1) have resulted in an increased understanding of this disorder which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN1 has improved patient management and treatment...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1677/erc.0.0060449

    authors： Pannett AA,Thakker RV

    更新日期：1999-12-01 00:00:00

  • Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.

    abstract：:We report the case of an 8-year-old child who presented with severe hyperinsulinaemic hypoglycaemia due to a pancreatic islet cell adenoma. In vivo, there was no beneficial response to the hyperglycaemia-inducing agent diazoxide and as a consequence the child underwent a subtotal pancreatectomy. In vitro studies of ad...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/erc.0.0090221

    authors： Hussain K,Cosgrove KE,Shepherd RM,Chapman JC,Swift SM,Smith VV,Kassem SA,Glaser B,Lindley KJ,Aynsley-Green A,Dunne MJ

    更新日期：2002-12-01 00:00:00

  • Stem cells in genetically-engineered mouse models of prostate cancer.

    abstract：:The cancer stem cell model proposes that tumors have a hierarchical organization in which tumorigenic cells give rise to non-tumorigenic cells, with only a subset of stem-like cells able to propagate the tumor. In the case of prostate cancer, recent analyses of genetically engineered mouse (GEM) models have provided e...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-15-0367

    authors： Shibata M,Shen MM

    更新日期：2015-12-01 00:00:00

  • Resveratrol and cancer: focus on in vivo evidence.

    abstract：:Resveratrol is a naturally occurring polyphenol that provides a number of anti-aging health benefits including improved metabolism, cardioprotection, and cancer prevention. Much of the work on resveratrol and cancer comes from in vitro studies looking at resveratrol actions on cancer cells and pathways. There are, how...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-13-0171

    authors： Carter LG,D'Orazio JA,Pearson KJ

    更新日期：2014-05-06 00:00:00

  • Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.

    abstract：:Certain members of the thiazolidinedione (TZD) family of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, such as troglitazone and ciglitazone, exhibit antitumor activities; however, the underlying mechanism remains inconclusive. Substantial evidence suggests that the antiproliferative effect...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1677/erc.1.01182

    authors： Weng JR,Chen CY,Pinzone JJ,Ringel MD,Chen CS

    更新日期：2006-06-01 00:00:00

  • Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.

    abstract：:This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2-4, N0-1, M0 breast cancer wer...

    journal_title：Endocrine-related cancer

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1677/erc.1.00945

    authors： Bottini A,Berruti A,Brizzi MP,Bersiga A,Generali D,Allevi G,Aguggini S,Bolsi G,Bonardi S,Tondelli B,Vana F,Tampellini M,Alquati P,Dogliotti L

    更新日期：2005-06-01 00:00:00

  • lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling.

    abstract：:Pancreatic neuroendocrine neoplasms (pNENs) are endocrine tumors arising in pancreas and is the most common neuroendocrine tumors. Mounting evidence indicates lncRNA H19 could be a determinant of tumor progression. However, the expression and mechanism of H19 and the relevant genes mediated by H19 in pNENs remain unde...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-18-0552

    authors： Ji M,Yao Y,Liu A,Shi L,Chen D,Tang L,Yang G,Liang X,Peng J,Shao C

    更新日期：2019-07-01 00:00:00

  • LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.

    abstract：:Platinum-based therapy remains the cornerstone for cancer therapy; however, its efficacy varies. The role of lipoprotein receptor-mediated lipid entry for cancer development has been reported. Yet, the roles and mechanism of the low-density lipoprotein receptor (LDLR) in chemo-sensitivities are unknown. In the current...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-19-0095

    authors： Chang WC,Wang HC,Cheng WC,Yang JC,Chung WM,Ho YP,Chen L,Hung YC,Ma WL

    更新日期：2020-02-01 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract：:Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1677/erc.0.0060333

    authors： Boyce BF,Yoneda T,Guise TA

    更新日期：1999-09-01 00:00:00

  • Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.

    abstract：:Deprivation of estrogen causes breast tumors in women to adapt and develop enhanced sensitivity to this steroid. Accordingly, women relapsing after treatment with oophorectomy, which substantially lowers estradiol for a prolonged period, respond secondarily to aromatase inhibitors with tumor regression. We have utiliz...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/erc.1.01018

    authors： Santen RJ,Song RX,Zhang Z,Kumar R,Jeng MH,Masamura A,Lawrence J Jr,Berstein L,Yue W

    更新日期：2005-07-01 00:00:00

  • Metabolomics signatures of a subset of RET variants according to their oncogenic risk level.

    abstract：:Thirty percent of medullary thyroid carcinomas (MTCs) are related to dominant germline pathogenic variants in the RET proto-oncogene. According to their aggressiveness, these pathogenic variants are classified in three risk levels: 'moderate', 'high' and 'highest'. The present study compares the metabolomics profiles ...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1530/ERC-18-0314

    authors： Veyrat-Durebex C,Bouzamondo N,Le Mao M,Chao de la Barca JM,Bris C,Dieu X,Simard G,Gadras C,Tessier L,Drui D,Borson-Chazot F,Barlier A,Reynier P,Prunier-Mirebeau D

    更新日期：2019-03-01 00:00:00

  • Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.

    abstract：:The imprinted gene, neuronatin (NNAT), is one of the most abundant transcripts in the pituitary and is thought to be involved in the development and maturation of this gland. In a recent whole-genome approach, exploiting a pituitary tumour cell line, we identified hypermethylation associated loss of NNAT. In this repo...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章

    doi：10.1677/ERC-09-0008

    authors： Revill K,Dudley KJ,Clayton RN,McNicol AM,Farrell WE

    更新日期：2009-06-01 00:00:00

  • FOXO factors and breast cancer: outfoxing endocrine resistance.

    abstract：:The majority of metastatic breast cancers cannot be cured and present a major public health problem worldwide. Approximately 70% of breast cancers express the estrogen receptor, and endocrine-based therapies have significantly improved patient outcomes. However, the development of endocrine resistance is extremely com...

    journal_title：Endocrine-related cancer

    pub_type： 杂志文章,评审

    doi：10.1530/ERC-15-0461

    authors： Bullock M

    更新日期：2016-02-01 00:00:00